DocDollars

Avanir Pharmaceuticals, Inc.

CA · United States · Reporting entity ID 100000005729

Total reported 2019–2025
$39.5M
#199 of 2,960 reporting companies — 0% of all reported industry payments
$6.69M in general payments across 79,399 records, plus $32.8M in research funding across 3,719 records.

How it breaks down

General payments $6,688,438
Research funding $32,837,486

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Avanir Pharmaceuticals, Inc. reported $39.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #199 of 2,960 reporting companies. 83% of that was research funding and 17% general payments such as consulting, speaking, food and travel. 79,399 general payment records and 3,719 research records were filed.

Common questions about Avanir Pharmaceuticals, Inc.

How much has Avanir Pharmaceuticals, Inc. paid US doctors?

Avanir Pharmaceuticals, Inc. reported $39,525,924 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $6,688,438 in general payments, $32,837,486 in research funding.

How does Avanir Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #199 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Avanir Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.